Docetaxel Plus Cisplatin Followed by Gemcitabine Versus Gemcitabine Plus Cisplatin Followed by Docetaxel for Non-Small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
About this trial
This is an interventional treatment trial for Non-small Cell Lung Cancer focused on measuring Combination, Chemotherapy,non-small cell lung cancer
Eligibility Criteria
Inclusion Criteria: Histologic or cytologic diagnosis of stage IIIB/IV NSCLC, no prior chemotherapy Age > 18 years and < 75 years WHO PS: 0,1 Unidimensional or bi-dimensional measurable disease Neutrophils > 1.5 109/l, Platelets > 100 109/l, Hemoglobin > 10g/dl, Total bilirubin < 1.5 UNL, AST (SGOT) and ALT (SGPT) < 2.5 UNL, Alkaline phosphatases < 5 UNL; except in presence of only bone metastasis and in the absence of any liver disorders Creatinine < 1 UNL, and creatinine clearance should be > 60 ml/min. Life expectancy > 12 weeks Exclusion Criteria: Pregnant, or lactating patients Known clinical brain or leptomeningeal involvement Pre-existing motor or sensory neurotoxicity of a severity > grade 1 by NCIC-CTG criteria CHF, angina or arrhythmias History of significant neurological or psychiatric disorders Active uncontrolled infection Contraindication for the use of corticosteroids Concurrent treatment with other experimental drugs within 30 days prior to study entry Concurrent treatment with any other anti-cancer therapy
Sites / Locations
- Department of Oncology, National Taiwan University Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
A
B